Abstract
Diabetic neuropathy (DN) is the most challenging microvascular complication of diabetes and there is no suitable treatment for it, so the development of new agents to relieve DN is urgently needed. Since oxidative stress and inflammation play an essential role in the development of DN, clearance of these factors are good strategies for the treatment of this disease. According to key role of cyclic adenosine monophosphate (cAMP) in the regulation of oxidative stress and inflammatory pathways, it seems that phosphodiesterase inhibitors (PDEIs) can be as novel drug targets for improving DN through enhancement of cAMP level. The aim of this study was to evaluate the effects of rolipram, a selective PDE4 inhibitor, and pentoxifylline, a general PDE inhibitor on experimental model of DN and also to determine the possible mechanisms involved in the effectiveness of these agents. We investigated the effects of rolipram (1 mg/kg) and pentoxifylline (100 mg/kg) and also combination of rolipram (0.5 mg/kg) and pentoxifylline (50 mg/kg), orally for five weeks in rats that became diabetic by STZ (55 mg/kg, i.p.). After treatments, motor function was evaluated by open-field test, then rats were anesthetized and dorsal root ganglion (DRG) neurons isolated. Next, oxidative stress biomarkers and inflammatory factors were assessed by biochemical and ELISA methods, and RT-PCR analysis in DRG neurons. Rolipram and/or pentoxifylline treatment significantly attenuated DN – induced motor function deficiency by modulating distance moved and velocity. Rolipram and/or pentoxifylline treatment dramatically increased the cAMP level, as well as suppressed DN – induced oxidative stress which was associated with decrease in LPO and ROS and increase in TAC, total thiol, CAT and SOD in DRG neurons. On the other hand, the level of inflammatory factors (TNF-α, NF-kB and COX2) significantly decreased following rolipram and/or pentoxifylline administration. The maximum effectiveness was with rolipram and/or pentoxifylline combination on mentioned factors. These findings provide novel experimental evidence for further clinical investigations on rolipram and pentoxifylline combination for the treatment of DN.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
All data generated or analyzed during this study are included in this published article.
Change history
11 October 2023
A Correction to this paper has been published: https://doi.org/10.1007/s11011-023-01305-4
References
Amour AA, Chamba N, Kayandabila J, Lyaruu IA, Marieke D, Shao ER, Howlett W (2019) Prevalence, patterns, and factors associated with peripheral neuropathies among diabetic patients at tertiary Hospital in the Kilimanjaro Region: descriptive cross-sectional study from North-Eastern Tanzania. Int J Endocrinol 2019:7p. https://doi.org/10.1155/2019/5404781
Bao F, Fleming JC, Golshani R, Pearse DD, Kasabov L, Brown A, Weaver LC (2011) A selective phosphodiesterase-4 inhibitor reduces leukocyte infiltration, oxidative processes, and tissue damage after spinal cord injury. J Neurotrauma 28(6):1035–1049. https://doi.org/10.1089/neu.2010.1575
Benzi IF, Strain S (1999) Ferric reducing antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. Methods Enzymol 292:15–27. https://doi.org/10.1016/S0076-6879(99)99005-5
Bertolotto F, Massone A (2012) Combination of alpha lipoic acid and superoxide dismutase leads to physiological and symptomatic improvements in diabetic neuropathy. Drugs R D 12(1):29–34. https://doi.org/10.2165/11599200-000000000-00000
Beshay E, Croze F, Prud'homme GJ (2001) The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo. Clin Immunol 98(2):272–279. https://doi.org/10.1006/clim.2000.4964
Bönhof GJ, Herder C, Strom A, Papanas N, Roden M, Ziegler D (2019) Emerging biomarkers, tools, and treatments for diabetic polyneuropathy. Endocr Rev 40:153–192. https://doi.org/10.1210/er.2018-00107
Cho N, Shaw JE, Karuranga S, Huang YD, da Rocha Fernandes JD, Ohlrogge AW, Malanda B (2018) IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 138:271–281. https://doi.org/10.1016/j.diabres.2018.02.023
Chung KF (2006) Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 533(1-3):110–117. https://doi.org/10.1016/j.ejphar.2005.12.059
Cohen KL, Harris S (1987) Pentoxifylline and diabetic neuropathy. Ann Intern Med 107(4):600–601. https://doi.org/10.7326/0003-4819-107-4-600_2
Cohen SM, Mathews T (1991) Pentoxifylline in the treatment of distal diabetic neuropathy. Angiology 42(9):741–746. https://doi.org/10.1177/000331979104200908
Davidson EP, Coppey LJ, Dake B, Yorek MA (2011) Treatment of Streptozotocin-induced diabetic rats with Alogliptin: effect on vascular and neural complications. Exp Diabetes Res 2011:810469. https://doi.org/10.1155/2011/810469
de Oliveira Garcia FA, Rebouças JF, Balbino TQ, da Silva TG, de Carvalho-Júnior CHR, Cerqueira GS, de Castro Brito GA, de Barros Viana GS (2015) Pentoxifylline reduces the inflammatory process in diabetic rats: relationship with decreases of pro-inflammatory cytokines and inducible nitric oxide synthase. J Inflamm 12(1):1–10. https://doi.org/10.1186/s12950-015-0080-5
Dewanjee S, Das S, Das AK, Bhattacharjee N, Dihingia A, Dua TK, Kalita J, Manna P (2018) Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets. Eur J Pharmacol 833:472–523. https://doi.org/10.1016/j.ejphar.2018.06.034
Flint H, Cotter MA, Cameron NE (2000) Pentoxifylline effects on nerve conduction velocity and blood flow in diabetic rats. Int J Exp Diabetes Res 1(1):49–58. https://doi.org/10.1155/edr.2000.49
Galeshkalami NS, Abdollahi M, Najafi R, Baeeri M, Jamshidzade A, Falak R, Gholami MD, Hassanzadeh G, Mokhtari T, Hassani S (2019) Alpha-lipoic acid and coenzyme Q10 combination ameliorates experimental diabetic neuropathy by modulating oxidative stress and apoptosis. Life Sci 216:101–110. https://doi.org/10.1016/j.lfs.2018.10.055
Ghaznavi H, Najafi R, Mehrzadi S, Hosseini A, Tekyemaroof N, Shakeri-Zadeh A, Rezayat M, Sharifi AM (2015) Neuro-protective effects of cerium and yttrium oxide nanoparticles on high glucose-induced oxidative stress and apoptosis in undifferentiated PC12 cells. Neurol Res 37(7):624–632. https://doi.org/10.1179/1743132815Y.0000000037
Giembycz MA, Newton R (2011) Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies. Handb Exp Pharmacol 204:415–446. https://doi.org/10.1007/978-3-642-17969-3_18
Goldin A, Beckman JA, Schmidt AM, Creager MA (2006) Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114(6):597–605. https://doi.org/10.1161/CIRCULATIONAHA.106.621854
Halis H, Bitiktaş S (2019) Differential effects of Pentoxifylline on learning and memory impairment induced by hypoxic-ischemic brain injury in rats. Clin Psychopharmacol Neurosci 17(3):388–399. https://doi.org/10.9758/cpn.2019.17.3.388
Han KH, Kim SH, Jeong IC, Lee YH, Chang SJ, Park BNR, Kim SW (2012) Electrophysiological and behavioral changes by phosphodiesterase 4 inhibitor in a rat model of alcoholic neuropathy. J Korean Neurosurg Soc 52(1):32–36. https://doi.org/10.3340/jkns.2012.52.1.32
Hannila SS, Filbin MT (2008) The role of cyclic AMP signaling in promoting axonal regeneration after spinal cord injury. Exp Neurol 209(2):321–332. https://doi.org/10.1016/j.expneurol.2007.06.020
Hayden MS, Ghosh S (2008) Shared principles in NF-κB signaling. Cell 132(3):344–362
Hosseini A, Abdollahi M (2013) Diabetic neuropathy and oxidative stress: therapeutic perspectives. Oxidative Med Cell Longev 2013:168039. https://doi.org/10.1155/2013/168039
Hosseini A, Abdollahi M, Hassanzadeh G, Rezayat M, Hassani S, Pourkhalili N, Tabrizian K, Khorshidahmad T, Beyer C, Sharifzadeh M (2011) Protective effect of magnesium-25 carrying porphyrin-fullerene nanoparticles on degeneration of dorsal root ganglion neurons and motor function in experimental diabetic neuropathy. Basic Clin Pharmacol Toxicol 109(5):381–386. https://doi.org/10.1111/j.1742-7843.2011.00741.x
Hosseini A, Sharifi AM, Abdollahi M, Najafi R, Baeeri M, Rayegan S, Cheshmehnour J, Hassani S, Bayrami Z, Safa M (2015) Cerium and yttrium oxide nanoparticles against lead-induced oxidative stress and apoptosis in rat hippocampus. Biol Trace Elem Res 164(1):80–89. https://doi.org/10.1007/s12011-014-0197-z
Hosseini A, Sharifzadeh M, Rezayat SM, Hassanzadeh G, Hassani S, Baeeri M, Shetab-Bushehri V, Kuznetsov DA, Abdollahi M (2010) Benefit of magnesium-25 carrying porphyrin-fullerene nanoparticles in experimental diabetic neuropathy. Int J Nanomedicine 5:517–523. https://doi.org/10.2147/ijn.s11643
Hosseini F, Mohammadbeigi A, Aghaali M, Borujerdi R, Parham M (2019) Effect of pentoxifylline on diabetic distal polyneuropathy in type 2 diabetic patients: a randomized trial. J Res Med Sci 24:89. https://doi.org/10.4103/jrms.JRMS_115_18
Houslay MD, Schafer P, Zhang KY (2005) Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10(22):1503–1519. https://doi.org/10.1016/S1359-6446(05)03622-6
Hu ML, Dillared CJ (1994) Plasma SH and GSH measurement. Methods Enzymol 233:385–387
Javed S, Alam U, Malik RA (2015) Burning through the pain: treatments for diabetic neuropathy. Diabetes Obes Metab 17(12):1115–1125. https://doi.org/10.1111/dom.12535
Kajana S, Goshgarian HG (2008) Administration of phosphodiesterase inhibitors and an adenosine A1 receptor antagonist induces phrenic nerve recovery in high cervical spinal cord injured rats. Exp Neurol 210(2):671–680. https://doi.org/10.1016/j.expneurol.2007.12.021
Kalmansohn RB, Kalmansohn RW, Markham CH, Schiff DL (1988) Treatment of diabetic neuropathy with pentoxifylline: case report. Angiology 39(4):371–374. https://doi.org/10.1177/000331978803900407
Khasraghi AA, Baeeri M, Payandemehr B, Rezaeiroushan M, Vakilzadeh G, Hassani S, Hosseini A, Hassanzadeh G, Dehpour AR, Sharifzadeh M (2018) Lithium decreases streptozocin-induced diabetic neuropathy in rats by inhibiting of adenosine triphosphate (ATP) degradation. Acta Med Iran:151–160
Kilanowska A, Ziolkowska A (2020) Role of Phosphodiesterase in the biology and pathology of diabetes. Int J Mol Sci 21(21):8244. https://doi.org/10.3390/ijms21218244
Kim HK, Hwang SH, Lee SO, Kim SH, Abdi S (2016) Pentoxifylline ameliorates mechanical Hyperalgesia in a rat model of chemotherapy-induced neuropathic pain. Pain Physician 19(4):E589–E600. https://doi.org/10.36076/ppj/2019.19.E589
Kim HK, Kwon JY, Yoo C, Abdi S (2015) The analgesic effect of Rolipram, a Phosphodiesterase 4 inhibitor, on chemotherapy-induced neuropathic pain in rats. Anesth Analg 121(3):822–828. https://doi.org/10.1213/ANE.0000000000000853
Kim SH, Park BN, Kim SW (2011) The effect of phosphodiesterase-4-specific inhibitor in the rat model of spinal nerve ligation. J Korean Neurosurg Soc 50(2):109–113. https://doi.org/10.3340/jkns.2011.50.2.109
Kishi M, Tanabe J, Schmelzer JD, Low PA (2002) Morphometry of dorsal root ganglion in chronic experimental diabetic neuropathy. Diabetes 51(3):819–824. https://doi.org/10.2337/diabetes.51.3.819
Kreth S, Ledderose C, Luchting B, Weis F, Thiel M (2010) Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways. Shock 34(1):10–16. https://doi.org/10.1097/SHK.0b013e3181cdc3e2
Laczy B, Cseh J, Mohas M, Marko L, Tamasko M, Koszegi T, Molnar GA, Wagner Z, Wagner L, Wittmann I (2009) Effects of pentoxifylline and pentosan polysulphate combination therapy on diabetic neuropathy in type 2 diabetes mellitus. Acta Diabetol 46(2):105–111. https://doi.org/10.1007/s00592-008-0064-5
LeBel CP, Ischiropoulos H, Bondy SC (1992) Evaluation of the probe 2',7'-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol 5(2):227–231. https://doi.org/10.1021/tx00026a012
Lee Y, Robinson M, Wong N, Chan E, Charles MA (1997) The effect of pentoxifylline on current perception thresholds in patients with diabetic sensory neuropathy. J Diabetes Complicat 11(5):274–278. https://doi.org/10.1016/s1056-8727(96)00077-3
Liu J, Feng X, Yu M, Xie W, Zhao X, Li W, Guan R, Xu J (2007) Pentoxifylline attenuates the development of hyperalgesia in a rat model of neuropathic pain. Neurosci Lett 412(3):268–272. https://doi.org/10.1016/j.neulet.2006.11.022
Lonze BE, Ginty DD (2002) Function and regulation of CREB family transcription factors in the nervous system. Neuron 35(4):605–623. https://doi.org/10.1016/s0896-6273(02)00828-0
Luna T, Santos SB, Nascimento M, Porto MA, Muniz AL, Carvalho EM, Jesus AR (2011) Effect of TNF-alpha production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individuals. Braz J Med Biol Res 44(11):1134–1140. https://doi.org/10.1590/s0100-879x2011007500140
Mallet ML, Hadjivassiliou M, Sarrigiannis PG, Zis P (2020) The role of oxidative stress in peripheral neuropathy. J Mol Neurosci 70(7):1009–1017. https://doi.org/10.1007/s12031-020-01495-x
Milani E, Nikfar S, Khorasani R, Zamani MJ, Abdollahi M (2005) Reduction of diabetes-induced oxidative stress by phosphodiesterase inhibitors in rats. Comp Biochem Physiol C Toxicol Pharmacol 140(2):251–255. https://doi.org/10.1016/j.cca.2005.02.010
Miroliaee AE, Esmaily H, Vaziri-Bami A, Baeeri M, Shahverdi AR, Abdollahi M (2011) Amelioration of experimental colitis by a novel nanoselenium–silymarin mixture. Toxicol Mech Methods 21(3):200–208. https://doi.org/10.3109/15376516.2010.547887
Mokry J, Joskova M, Mokra D, Christensen I, Nosalova G (2013) Effects of selective inhibition of PDE4 and PDE7 on airway reactivity and cough in healthy and ovalbumin-sensitized guinea pigs. Adv Exp Med Biol 756:57–64. https://doi.org/10.1007/978-94-007-4549-0_8
Najafi R, Hosseini A, Ghaznavi H, Mehrzadi S, Sharifi AM (2017) Neuroprotective effect of cerium oxide nanoparticles in a rat model of experimental diabetic neuropathy. Brain Res Bull 131:117–122. https://doi.org/10.1016/j.brainresbull.2017.03.013
Najafi R, Sharifi AM, Hosseini A (2015) Protective effects of alpha lipoic acid on high glucose-induced neurotoxicity in PC12 cells. Metab Brain Dis 30(3):731–738. https://doi.org/10.1007/s11011-014-9625-1
Neves KRT, Nobre HV, Leal LKA, de Andrade GM, Brito GAC, Viana GSB (2015) Pentoxifylline neuroprotective effects are possibly related to its anti-inflammatory and TNF-alpha inhibitory properties, in the 6-OHDA model of Parkinson’s disease. Parkinson’s Dis 2015. https://doi.org/10.1155/2015/108179
Obrosova IG (2009) Diabetes and the peripheral nerve. Biochim Biophys Acta 1792(10):931–940. https://doi.org/10.1016/j.bbadis.2008.11.005
Okayama A, Mikasa K, Matsui N, Higashi N, Miyamoto M, Kita E (2004) An interventional approach to block brain damage caused by Shiga toxin-producing Escherichia coli infection, by use of a combination of phosphodiesterase inhibitors. J Infect Dis 190(12):2129–2136. https://doi.org/10.1086/425982
Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95(2):351–358. https://doi.org/10.1016/0003-2697(79)90738-3
Oyenihi AB, Ayeleso AO, Mukwevho E, Masola B (2015) Antioxidant strategies in the management of diabetic neuropathy. Biomed Res Int 2015:515042. https://doi.org/10.1155/2015/515042
Perez-Aso M, Montesinos MC, Mediero A, Wilder T, Schafer PH, Cronstein B (2015) Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Arthritis Res Ther 17(1):1–13. https://doi.org/10.1186/s13075-015-0771-6
Pope JE, Deer TR, Kramer J (2013) A systematic review: current and future directions of dorsal root ganglion therapeutics to treat chronic pain. Pain Med 14(10):1477–1496. https://doi.org/10.1111/pme.12171
Radfar M, Larijani B, Hadjibabaie M, Rajabipour B, Mojtahedi A, Abdollahi M (2005) Effects of pentoxifylline on oxidative stress and levels of EGF and NO in blood of diabetic type-2 patients; a randomized, double-blind placebo-controlled clinical trial. Biomed Pharmacother 59(6):302–306. https://doi.org/10.1016/j.biopha.2005.05.003
Russell JW, Zilliox LA (2014) Diabetic neuropathies. Continuum (Minneap Minn) 20:1226–1240. https://doi.org/10.1212/01.CON.0000455884.29545.d2
Saberi Firouzi S, Namazi Sarvestani N, Bakhtiarian A, Ghazi Khansari M, Karimi MY, Ranjbar A, Safa M, Hosseini A (2018) Sildenafil protective effects on high glucose-induced neurotoxicity in PC12 cells: the role of oxidative stress, apoptosis, and inflammation pathways in an in vitro cellular model for diabetic neuropathy. Neurol Res 40(8):624–636. https://doi.org/10.1080/01616412.2018.1458813
Sandireddy R, Yerra VG, Areti A, Komirishetty P, Kumar A (2014) Neuroinflammation and oxidative stress in diabetic neuropathy: futuristic strategies based on these targets. Int J Endocrinol 2014. https://doi.org/10.1155/2014/674987
Sarvestani NN, Firouzi SS, Falak R, Karimi MY, Gholami MD, Rangbar A, Hosseini A (2018) Phosphodiesterase 4 and 7 inhibitors produce protective effects against high glucose-induced neurotoxicity in PC12 cells via modulation of the oxidative stress, apoptosis and inflammation pathways. Metab Brain Dis 33(4):1293–1306. https://doi.org/10.1007/s11011-018-0241-3
Satoh J, Yagihashi S, Toyota T (2003) The possible role of tumor necrosis factor-alpha in diabetic polyneuropathy. Exp Diabesity Res 4(2):65–71. https://doi.org/10.1155/EDR.2003.65
Sharifzadeh M, Ranjbar A, Hosseini A, Khanavi M (2017) The effect of green tea extract on oxidative stress and spatial learning in Streptozotocin-diabetic rats. Iran J Pharm Res 16(1):201–209
Shi Y, Liang X-c, Zhang H, Wu Q-l, Qu L, Sun Q (2013) Quercetin protects rat dorsal root ganglion neurons against high glucose-induced injury in vitro through Nrf-2/HO-1 activation and NF-κB inhibition. Acta Pharmacol Sin 34(9):1140–1148. https://doi.org/10.1038/aps.2013.59
Sinha KA (1972) Colorimetric assay of catalase. Anal Biochem 47:389–394. https://doi.org/10.1016/0003-2697(72)90132-7
Sytze van Dam P (2002) Oxidative stress and diabetic neuropathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 18(3):176–184. https://doi.org/10.1002/dmrr.287
Troadec J-D, Marien M, Mourlevat S, Debeir T, Ruberg M, Colpaert F, Michel PP (2002) Activation of the mitogen-activated protein kinase (ERK1/2) signaling pathway by cyclic AMP potentiates the neuroprotective effect of the neurotransmitter noradrenaline on dopaminergic neurons. Mol Pharmacol 62(5):1043–1052. https://doi.org/10.1124/mol.62.5.1043
Vincent AM, Edwards JL, McLean LL, Hong Y, Cerri F, Lopez I, Quattrini A, Feldman EL (2010) Mitochondrial biogenesis and fission in axons in cell culture and animal models of diabetic neuropathy. Acta Neuropathol 120(4):477–489. https://doi.org/10.1007/s00401-010-0697-7
Vincent AM, Russell JW, Low P, Feldman EL (2004) Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 25(4):612–628. https://doi.org/10.1210/er.2003-0019
Volakakis N, Kadkhodaei B, Joodmardi E, Wallis K, Panman L, Silvaggi J, Spiegelman BM, Perlmann T (2010) NR4A orphan nuclear receptors as mediators of CREB-dependent neuroprotection. Proc Natl Acad Sci 107(27):12317–12322. https://doi.org/10.1073/pnas.1007088107
Yang D, Liang XC, Shi Y, Sun Q, Liu D, Liu W, Zhang H (2016) Anti-oxidative and anti-inflammatory effects of cinnamaldehyde on protecting high glucose-induced damage in cultured dorsal root ganglion neurons of rats. Chin J Integr Med 22(1):19–27. https://doi.org/10.1007/s11655-015-2103-8
Zhuo Y, Guo H, Cheng Y, Wang C, Wang C, Wu J, Zou Z, Gan D, Li Y, Xu J (2016) Inhibition of phosphodiesterase-4 reverses the cognitive dysfunction and oxidative stress induced by Aβ25–35 in rats. Metab Brain Dis 31(4):779–791. https://doi.org/10.1007/s11011-016-9814-1
Funding
This work was supported by Iran University of Medical Sciences (grant number: 96-01-118-29912).
Author information
Authors and Affiliations
Contributions
Mona Dastgheib: methodology, validation, investigation, data analysis, writing - original Draft; Seyed Vahid Shetab-Boushehri: investigation, review & editing; Maryam Baeeri: methodology, validation, investigation; Gholami Mahdi: methodology, validation; Mohammad Yahya Karimi: resources, methodology; Mohammad Abdollahi: review & editing; Asieh Hosseini: methodology, writing- review & editing, supervision, project administration, funding acquisition.
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Dastgheib, M., Shetab-Boushehri, S.V., Baeeri, M. et al. Rolipram and pentoxifylline combination ameliorates experimental diabetic neuropathy through inhibition of oxidative stress and inflammatory pathways in the dorsal root ganglion neurons. Metab Brain Dis 37, 2615–2627 (2022). https://doi.org/10.1007/s11011-022-01060-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11011-022-01060-y